Next Article in Journal
Hypertrophy-Promoting Effects of Leucine Supplementation and Moderate Intensity Aerobic Exercise in Pre-Senescent Mice
Next Article in Special Issue
Resveratrol Interferes with IL1-β-Induced Pro-Inflammatory Paracrine Interaction between Primary Chondrocytes and Macrophages
Previous Article in Journal
Chemopreventive Effect of Dietary Glutamineon Colitis-Associated Colorectal Cancer Is Associated with Modulation of the DEPTOR/mTOR Signaling Pathway
Previous Article in Special Issue
Resveratrol and Myopathy

Resveratrol and Cardiovascular Diseases

Department of Biochemistry, Faculty of Pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris 75006, France
Department of Metabolic Biochemistry, Pitié-Salpêtrière-Charles Foix Hospital (AP-HP), Paris 75013, France
Inserm UMR_S 1166 ICAN, UPMC, La Pitié Hospital, Paris 75013, France
Nutrients 2016, 8(5), 250;
Received: 28 February 2016 / Revised: 10 April 2016 / Accepted: 20 April 2016 / Published: 2 May 2016
(This article belongs to the Special Issue Selected Papers from Resveratrol Regional Meeting 2015)
The increased incidence of cardiovascular diseases (CVDs) has stimulated research for substances that could improve cardiovascular health. Among them, resveratrol (RES), a polyphenolic compound notably present in grapes and red wine, has been involved in the “French paradox”. RES is known for its antioxidant and anti-inflammatory properties and for its ability to upregulate endothelial NO synthase (eNOS). RES was able to scavenge OH/O2•− and peroxyl radicals, which can limit the lipid peroxidation processes. Moreover, in bovine aortic endothelial cells (BAEC) under glucose-induced oxidative stress, RES restored the activity of dimethylargininedimethylaminohydrolase (DDAH), an enzyme that degrades an endogenous inhibitor of eNOS named asymmetric dimethylarginine (ADMA). Thus, RES could improve NO availability and decrease the endothelial dysfunction observed in diabetes. Preclinical studies have made it possible to identify molecular targets (SIRT-1, AMPK, Nrf2, NFκB…); however, there are limited human clinical trials, and difficulties in the interpretation of results arise from the use of high-dose RES supplements in research studies, whereas low RES concentrations are present in red wine. The discussions on potential beneficial effects of RES in CVDs (atherosclerosis, hypertension, stroke, myocardial infarction, heart failure) should compare the results of preclinical studies with those of clinical trials. View Full-Text
Keywords: antioxidant; atherosclerosis; clinical; heart failure; hypertension; inflammation; myocardial infarction; preclinical; resveratrol antioxidant; atherosclerosis; clinical; heart failure; hypertension; inflammation; myocardial infarction; preclinical; resveratrol
Show Figures

Figure 1

MDPI and ACS Style

Bonnefont-Rousselot, D. Resveratrol and Cardiovascular Diseases. Nutrients 2016, 8, 250.

AMA Style

Bonnefont-Rousselot D. Resveratrol and Cardiovascular Diseases. Nutrients. 2016; 8(5):250.

Chicago/Turabian Style

Bonnefont-Rousselot, Dominique. 2016. "Resveratrol and Cardiovascular Diseases" Nutrients 8, no. 5: 250.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop